Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study

Author:

Houillier Caroline1,Taillandier Luc2,Dureau Sylvain3,Lamy Thierry4,Laadhari Mouna3,Chinot Olivier5,Moluçon-Chabrot Cecile6,Soubeyran Pierre7,Gressin Remy8,Choquet Sylvain1,Damaj Gandhi9,Thyss Antoine10,Abraham Julie11,Delwail Vincent12,Gyan Emmanuel13,Sanhes Laurence14,Cornillon Jérôme15,Garidi Reda16,Delmer Alain17,Tanguy Marie-Laure13,Al Jijakli Ahmad18,Morel Pierre19,Bourquard Pascal20,Moles Marie-Pierre21,Chauchet Adrien22,Gastinne Thomas23,Constans Jean-Marc9,Langer Adriana3,Martin Antoine24,Moisson Patricia3,Lacomblez Lucette1,Martin-Duverneuil Nadine1,Delgadillo Daniel1,Turbiez Isabelle3,Feuvret Loïc1,Cassoux Nathalie3,Touitou Valérie1,Ricard Damien25,Hoang-Xuan Khê1,Soussain Carole3,

Affiliation:

1. Groupe Hospitalier Universitaire Pitié-Salpétrière, Paris, France

2. Centre Hospitalier Universitaire de Nancy, Nancy, France

3. Institut Curie, Site Saint-Cloud, Saint-Cloud, France

4. Centre Hospitalier Universitaire de Rennes, Rennes, France

5. Centre Hospitalier Universitaire de la Timone, Marseille, France

6. Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France

7. Institut Bergonié, Bordeaux, France

8. Centre Hospitalier Universitaire de Grenoble, La Tronche, France

9. Centre Hospitalier Universitaire d’Amiens, Salouël, France

10. Centre Antoine Lacassagne, Nice, France

11. Centre Hospitalier Universitaire de Limoges, Limoges, France

12. Centre Hospitalier Universitaire de Poitiers, Poitiers, France

13. Centre Hospitalier Regional Universitaire de Tours, Tours, France

14. Centre Hospitalier de Perpignan, Perpignan, France

15. Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France

16. Centre Hospitalier de Saint Quentin, Saint Quentin, France

17. Centre Hospitalier Universitaire de Reims, Reims, France

18. Centre Hospitalier d’Argenteuil, Argenteuil, France

19. Centre Hospitalier de Lens, Lens, France

20. Centre Hospitalier Universitaire de Nîmes, Nîmes, France

21. Centre Hospitalier Universitaire d’Angers, Angers, France

22. Centre Hospitalier Universitaire de Besançon, Besançon, France

23. Centre Hospitalier Universitaire de Nantes, Nantes, France

24. Hôpital Avicenne, Bobigny, France

25. Hôpital d’Instruction des Armées Percy, Clamart, France

Abstract

PURPOSE To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). PATIENTS AND METHODS Immunocompetent patients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as consolidation treatment after induction chemotherapy consisting of two cycles of R-MBVP (rituximab 375 mg/m2 day (D) 1, methotrexate 3 g/m2 D1; D15, VP16 100 mg/m2 D2, BCNU 100 mg/m2 D3, prednisone 60 mg/kg/d D1-D5) followed by two cycles of R-AraC (rituximab 375 mg/m2 D1, cytarabine 3 g/m2 D1 to D2). Intensive chemotherapy consisted of thiotepa (250 mg/m2/d D9; D8; D7), busulfan (8 mg/kg D6 through D4), and cyclophosphamide (60 mg/kg/d D3; D2). WBRT delivered 40 Gy (2 Gy/fraction). The primary end point was 2-year progression-free survival. Cognitive outcome was the main secondary end point. Analysis was intention to treat in a noncomparative phase II trial. RESULTS Between October 2008 and February 2014, 140 patients were recruited from 23 French centers. Both WBRT and ASCT met the predetermined threshold (among the first 38 patients in each group, at least 24 patients were alive and disease free at 2 years). The 2-year progression-free survival rates were 63% (95% CI, 49% to 81%) and 87% (95% CI, 77% to 98%) in the WBRT and ASCT arms, respectively. Toxicity deaths were recorded in one and five patients after WBRT and ASCT, respectively. Cognitive impairment was observed after WBRT, whereas cognitive functions were preserved or improved after ASCT. CONCLUSION WBRT and ASCT are effective consolidation treatments for patients with PCNSL who are 60 years of age and younger. The efficacy end points tended to favor the ASCT arm. The specific risk of each procedure should be considered.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3